Published 2012
| Version v1
Publication
Preliminary safety results of an Italian early-access program (EAP) with cabazitaxel plus prednisone (CbzP) in patients with docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC)
Additional details
- URL
- http://hdl.handle.net/11567/870119
- URN
- urn:oai:iris.unige.it:11567/870119
- Origin repository
- UNIGE